Paracetamol's Safety in Pregnancy: A Comprehensive Study Debunks Autism Link
A recent study has provided compelling evidence to reassure pregnant women and healthcare providers about the safety of paracetamol use. The research, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, thoroughly examined the relationship between paracetamol and various developmental disorders in children.
The study's findings are particularly significant given the controversy sparked by former US President Donald Trump's claim that paracetamol use during pregnancy increases the risk of autism. The research team conducted a systematic review and meta-analysis, analyzing 43 studies and 17 meta-analyses, with a focus on sibling-comparison studies and those with longer-term follow-ups, while excluding research with a high risk of bias.
The authors concluded that the previously reported associations between paracetamol and autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and intellectual disability are likely due to residual confounding factors such as maternal illness, fever, genetic susceptibility, or environmental influences. They emphasize that these factors are not directly linked to paracetamol use.
The study also highlights the potential risks of avoiding paracetamol based on inconclusive evidence. The authors caution that such avoidance could lead to increased maternal fever or untreated pain, both of which can negatively impact pregnancy outcomes. They recommend future research to improve exposure measurement, standardize outcome definitions, and incorporate mechanistic and family-based designs to address any remaining uncertainties.
The study's findings support the safety of paracetamol when used appropriately during pregnancy. Alex Polyakov, an obstetrician, gynaecologist, and fertility specialist, praised the study for offering "timely and methodologically rigorous reassurance." He noted that paracetamol has been a cornerstone of obstetric practice for decades due to its proven safety profile in managing pain and fever during pregnancy.
Polyakov addressed the public debate caused by selective interpretation of observational data, which had led to understandable anxiety. He emphasized that the study's approach, prioritizing sibling-comparison designs and studies at low risk of bias, effectively tackled the issue of confounding by indication, familial genetics, and shared environmental factors that had plagued earlier analyses.
The study's conclusions are significant, as they provide a comprehensive and evidence-based perspective on paracetamol's safety in pregnancy. By addressing the potential biases in earlier studies, the research team has concluded that prenatal paracetamol exposure is not associated with an increased risk of ASD, ADHD, or intellectual disability. The pooled estimates are not only null but also sufficiently precise to rule out any clinically meaningful harm.
This study is particularly relevant given the White House's recent citation of studies suggesting a link between paracetamol during pregnancy and ASD or ADHD. Many health organizations, including the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, have expressed serious doubts about the scientific basis of these claims. The study's findings are expected to alleviate concerns among healthcare providers and pregnant women, ensuring that paracetamol can continue to be used safely and effectively during pregnancy.
